China Medical System Holdings Limited (CHSYF)
OTCMKTS · Delayed Price · Currency is USD
1.350
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
CHSYF Revenue
China Medical System Holdings had revenue of 4.00B CNY in the half year ending June 30, 2025, a decrease of -13.19%. This brings the company's revenue in the last twelve months to 7.86B, up 12.06% year-over-year. In the year 2024, China Medical System Holdings had annual revenue of 7.47B, down -6.79%.
Revenue (ttm)
7.86B CNY
Revenue Growth
+12.06%
P/S Ratio
4.22
Revenue / Employee
1.29M CNY
Employees
6,095
Market Cap
4.63B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.47B | -544.30M | -6.79% |
| Dec 31, 2023 | 8.01B | -1.14B | -12.43% |
| Dec 31, 2022 | 9.15B | 813.13M | 9.75% |
| Dec 31, 2021 | 8.34B | 1.39B | 20.03% |
| Dec 31, 2020 | 6.95B | 872.34M | 14.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
China Medical System Holdings News
- 2 months ago - CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China - GlobeNewsWire
- 3 months ago - CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu® - GlobeNewsWire